Choose a language and wait for the translated text.
Shots:
CStone Pharmaceuticals has entered a clinical collaboration with Kimia Therapeutics to advance a first-in-class DNA damage response (DDR) inhibitor for solid tumors, with CStone leading clinical development in mainland China and Australia
The planned P-I study will include dose-escalation and expansion cohorts in biomarker-selected patients, assessing safety, pharmacokinetics, pharmacodynamics and early clinical activity to establish initial proof-of-concept
Under the co-development model, Kimia will provide clinical supply, scientific guidance and regulatory oversight, while reimbursing development costs. CStone is also eligible for milestone payments and royalties on global net sales, combining both companies’ complementary strengths.
Ref: PRnewswire | Image: CStone & Kimia | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
The post CStone Pharmaceuticals Partners with Kimia Therapeutics to Advance a DDR Inhibitor appeared first on PharmaShots.
